Trial Profile
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Dec 2023 Planned End Date changed from 1 Nov 2024 to 1 Nov 2025.
- 18 Dec 2023 Planned primary completion date changed from 28 Nov 2023 to 28 Nov 2024.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology